Vir Biotechnology, Inc. (VIR): Total Assets
$1.00B
As of 2025-12-31
$1.21B
As of 2026-06-30
-29.0%
3-year compound annual growth
+1.8%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.00B | -28.3% | 2026-02-23, Balance as of period end |
| 2024-12-31 | $1.40B | -27.1% | 2026-02-23, Balance as of period end |
| 2023-12-31 | $1.92B | -31.5% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $2.80B | +43.4% | 2024-02-26, Balance as of period end |
| 2021-12-31 | $1.95B | +112.7% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $918.76M | +79.4% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $512.07M | +167.3% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $191.60M | n/a | 2020-03-26, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $1.00B | -28.3% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $143.01M | +16.6% |
| Compugen Ltd (CGEN) | 2025-12-31 | $156.57M | +36.2% |
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | $1.47B | +1.8% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $589.07M | -24.7% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $26.99M | -16.6% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $244.43M | -9.4% |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $566.71M | +1.1% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $276.88M | +113.8% |
Compare VIR, BDTX, CGEN, RXRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗